Publication date: Sep 16, 2024
Cardiovascular disease (CVD) is a major health concern worldwide, particularly in low- and middle-income countries. The COVID-19 pandemic that emerged in late 2019 may have had an impact on the trend of CVD mortality. This study aimed to investigate the trend and changes in CVD mortality rates in Malaysia, using age-standardized mortality rates (ASMR) from 2010 to 2021. The Malaysian population and mortality data from 2010 to 2021 were obtained from the Department of Statistics Malaysia (DOSM). ASMRs from CVD per 100,000 population were calculated based on the World Health Organization (2000-2025) standard population using the direct method. The ASMRs were computed based on sex, age groups (including premature mortality age, 30-69 years), and CVD types. The annual percent change (APC) and average annual percent change (AAPC) of the ASMR with corresponding 95% confidence intervals (95% CI) were estimated from joinpoint regression model using the Joinpoint Regression Program, Version 4. 9.1. 0. Throughout the study period (2010-2021), ASMRs for CVD exhibited an increase from 93. 1 to 147. 0 per 100,000, with an AAPC of 3. 6% (95% CI: 2. 1 to 5. 2). The substantial increase was observed between 2015 and 2018 (APC 12. 6%, 95% CI: 5. 4%, 20. 3%), with significant changes in both sexes, and age groups 50-69, 70 years and over, and 30-69 (premature mortality age). Notably, the ASMR trend remained consistently high in the premature mortality age group across other age groups, with males experiencing higher rates than females. No significant changes were detected before or after the COVID-19 pandemic (between 2019 and 2021), except for females who died from IHD (10. 3% increase) and those aged 0-4 (25. 2% decrease). Overall, our analysis highlights the persistently high burden of CVD mortality in Malaysia, particularly among the premature mortality age group. These findings underscore the importance of continued efforts to address CVD risk factors and implement effective prevention and management strategies. Further research is needed to fully understand the impact of the COVID-19 pandemic on CVD mortality rates and to inform targeted interventions to reduce the burden of CVD in Malaysia.
Open Access PDF
Semantics
Type | Source | Name |
---|---|---|
disease | MESH | cardiovascular disease |
disease | MESH | COVID-19 pandemic |
disease | MESH | premature mortality |
pathway | REACTOME | Reproduction |
disease | MESH | death |
disease | MESH | stroke |
disease | MESH | obesity |
disease | MESH | hypertension |
drug | DRUGBANK | Ethanol |
disease | IDO | country |
disease | MESH | heart failure |
disease | MESH | infarction |
drug | DRUGBANK | Coenzyme M |
disease | IDO | intervention |
drug | DRUGBANK | Indoleacetic acid |
disease | MESH | cause of death |
disease | IDO | process |
drug | DRUGBANK | Esomeprazole |
disease | MESH | causes |
disease | MESH | lifestyle factors |
disease | IDO | blood |
disease | MESH | hypercholesterolemia |
disease | MESH | Morbidity |
disease | MESH | complications |
disease | MESH | cerebrovascular disease |
disease | MESH | myocardial infarction |
disease | MESH | vascular disease |
disease | MESH | Cancer |
disease | MESH | bladder cancer |
pathway | KEGG | Bladder cancer |
disease | IDO | site |
disease | MESH | communicable disease |
disease | MESH | ischemic heart disease |